Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne

Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that a Phase 1 clinical study of topical radezolid for the treatment of mild-to-moderate acne vulgaris has been successfully completed. Melinta and its partner enrolled 10 individuals with grade 3-to-4 acne vulgaris who applied topical radezolid twice daily for four weeks. Results demonstrated that radezolid was well tolerated with minimal systemic absorption.